Bristol Drops Virology Discovery In Latest R&D Reshuffling
This article was originally published in The Pink Sheet Daily
Firm plans to expand presence in Boston and San Francisco, while shuttering or de-emphasizing other locations, and to end virology discovery, in line with R&D strategy introduced in 2013.
You may also be interested in...
An attachment inhibitor entering Phase III may offer a new option for patients who have outlived the utility of other antiretrovirals. Bristol also is advancing a second-generation maturation inhibitor of HIV into Phase IIb studies, hoping to succeed where other candidates failed to address viral mutation.
Long-time senior VP of R&D Francis Cuss will succeed Elliott Sigal as Bristol’s head of R&D on July 1, following a transition period. In an investor call, Cuss indicated no great change in strategy but acknowledged an ongoing need to evolve corporate thinking and capability.
Two of the most prominent features of the House package are not addressed in the Senate measure, which predominantly focuses on cosmetics, dietary supplements and laboratory developed tests. The absence of competing proposals suggests a smooth conference process.